Evidence map›Paper›PMID 33875702›Full record

ArticleScientific reports2021

Evolution of antibody titres against Epstein-Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients.

Silvia Pérez-Pérez, Juan Pablo Cuello, Marisa Martínez-Ginés, Beatriz Pardo-Rodríguez, José Manuel García-Domínguez, María Inmaculada Domínguez-Mozo, Alberto Lozano-Ros, María Ángel García-Martínez, Yolanda Higueras, Ariana Meldaña-Rivera and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Silvia Pérez-PérezGrupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC) / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. silvip93@hotmail.com.
Juan Pablo CuelloServicio de Neurología, Hospital Universitario Gregorio Marañón / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Marisa Martínez-GinésServicio de Neurología, Hospital Universitario Gregorio Marañón / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Beatriz Pardo-RodríguezGrupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC) / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
José Manuel García-DomínguezServicio de Neurología, Hospital Universitario Gregorio Marañón / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
María Inmaculada Domínguez-MozoGrupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC) / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Alberto Lozano-RosServicio de Neurología, Hospital Universitario Gregorio Marañón / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
María Ángel García-MartínezGrupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC) / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Yolanda HiguerasInstituto de Investigación Sanitaria del Gregorio Marañón / Facultad de Psicología, Universidad Complutense de Madrid / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Ariana Meldaña-RiveraInstituto de Investigación Sanitaria del Gregorio Marañón / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Haydee Goicochea-BriceñoServicio de Neurología, Hospital Universitario Gregorio Marañón / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Amalia Tejeda-VelardeServicio de Inmunología, Hospital Universitario Ramón y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Jose Ignacio Fernández-VelascoServicio de Inmunología, Hospital Universitario Ramón y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Silvia MedinaServicio de Inmunología, Hospital Universitario Ramón y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Rafael ArroyoDepartmento de Neurología, Hospital Universitario Quironsalud Madrid / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Luisa María VillarServicio de Inmunología, Hospital Universitario Ramón y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Roberto Álvarez-LafuenteGrupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC) / Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Spanish Multiple Sclerosis Network · ESHospital Clínico San Carlos · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus (EBV), human herpesvirus 6A/B (HHV-6A/B) and multiple sclerosis (MS)-associated retrovirus (MSRV) have been described as possible MS triggers. We analysed antibody titres against EBV and HHV-6, and MSRV envelope (env) mRNA expression, in the serum of pregnant multiple sclerosis patients (P-MS) to study their possible link to the clinical activity of MS during pregnancy and postpartum and their possible role as relapse predictors. For that purpose, serum samples were collected from 71 pregnant women (50 pregnant MS and 21 pregnant healthy controls-P-HC) during pregnancy and postpartum. Relating to antibody titres, IgM antibody titres against HHV-6A/B were significantly higher in P-MS than in P-HC both in each pregnancy trimester and in the postpartum period. Moreover, IgM antibody titres against HHV-6A/B were higher in P-MS who suffered a relapse during the postpartum. Regarding MSRV env mRNA expression, the prevalence in the first trimester of pregnancy was significantly higher in P-MS who suffered relapses during pregnancy. Summing it up, high IgM antibody titres against HHV-6A/B and MSRV env mRNA expression during the first trimester of pregnancy could act as relapse predictors for the gestation/postpartum periods.

Indexed as

Multiple SclerosisAdultAntibodies, ViralBiomarkersEndogenous RetrovirusesEpstein-Barr Virus InfectionsFemaleHerpesvirus 1, CercopithecineHerpesvirus 4, HumanHerpesvirus 6, HumanHerpes ZosterHumansImmunoglobulin MPregnancyRNA, MessengerRNA, ViralAntibodies, ViralBiomarkersImmunoglobulin MRNA, MessengerRNA, ViralViral Envelope Proteins

Identifiers

PMID33875702
PMCPMC8055650
OpenAlexW3154661667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.